Key result
Transfection of the DNA-launched EV-A71 infectious clone produced virus yields comparable to in vitro-transcribed EV-A71 infectious RNA (6.44 vs 5.80 log10 PFU/ml).
Absolute Event Rate: 6.44% vs 5.8%
A novel DNA-launched infectious clone for EV-A71 offers a more efficient and cost-effective reverse genetics platform compared to traditional RNA transcription methods.
Novel DNA platform eases EV-A71 manipulation; extends reverse genetics tools but remains preclinical.
Enterovirus A71 (EV-A71) causes major outbreaks of hand, foot and mouth disease, and is occasionally associated with neurological complications and death in children. Reverse genetics is widely used in the field of virology for functional study of viral genes. For EV-A71, such tools are limited to clones that are transcriptionally controlled by T7/SP6 bacteriophage promoter. This is often time-consuming and expensive. Here, we describe the development of infectious plasmid DNA-based EV-A71 clones, for which EV-A71 genome expression is under transcriptional control by the CMV-intermediate early promoter and SV40 transcriptional-termination signal. Transfection of this EV-A71 infectious DNA produces good virus yield similar to in vitro-transcribed EV-A71 infectious RNA, 6.4 and 5.8 log10PFU/ml, respectively. Infectious plasmid with enhanced green fluorescence protein and Nano luciferase reporter genes also produced good virus titers, with 4.3 and 5.0 log10 PFU/ml, respectively. Another infectious plasmid with both CMV and T7 promoters was also developed for easy manipulation of in vitro transcription or direct plasmid transfection. Transfection with either dual-promoter infectious plasmid DNA or infectious RNA derived from this dual-promoter clone produced infectious viral particles. Incorporation of hepatitis delta virus ribozyme, which yields precise 3' ends of the DNA-launched EV-A71 genomic transcripts, increased infectious viral production. In contrast, the incorporation of hammerhead ribozyme in the DNA-launched EV-A71 resulted in lower virus yield, but improved the virus titers for T7 promoter-derived infectious RNA. This study describes rapid and robust reverse genetic tools for EV-A71.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2016) studied Enterovirus A71 infection (in vitro). DNA-launched EV-A71 infectious clones (pCMV-EV71) vs. In vitro-transcribed EV-A71 infectious RNA (pT7-EV71) was evaluated on Virus yield (log10 PFU/ml). Transfection of the DNA-launched EV-A71 infectious clone produced virus yields comparable to in vitro-transcribed EV-A71 infectious RNA (6.44 vs 5.80 log10 PFU/ml).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: